Eli Lilly and Company
COMPOUNDS AND METHODS TARGETING HUMAN TAU

Abstract:

The present invention provides compounds and methods targeting human tau, particularly human tau phosphorylated at threonine 217 and isoforms of tau expressed only in the CNS, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of neurodegenerative diseases such as AD, PSP and FTD.